In the angiogenesis condition, LRG1 modulates TGF-β to activate smad1/5 phosphorylation.11 LRG1 is a promising therapeutic target for pathogenic angiogenesis-associated disease, such as ocular disease, cancer and atherosclerosis,11 but it remains unclear whether LRG1 is increased and plays a role in OA or not. This evidence concerns the gene LRG1 and cancer.